证券代码：688198 证券简称：佰仁医疗 公告编号：2025-036 北京佰仁医疗科技股份有限公司 关于自愿披露ePTFE心包膜产品获批注册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 该产品为0.1mm的膨体聚四氟乙烯（ePTFE）膜，用于心脏外科手术中心包膜 的修复或重建。人体的心脏表面有一层薄膜包裹着整个心脏，这层薄膜被称为心包 或心包膜，对心脏表面组织，特别是对冠状动脉血管具有保护作用。每当需要进行 心外手术时，都不可避免地要切开心包膜，由于心包的外科损伤所致术后永久失去 原有心包膜，以致导致心脏表面裸露与胸骨组织粘连，使得再行开胸手术时面临出 血等严重并发症的风险，致使手术难度增加，特别是小儿复杂先心病患者，很多都 需要再次开胸。因此，开心手术常规需要植用心包膜（ePTFE）修复或重建破损心 包以保护心脏。目前国内市场所用的心包膜为外企垄断，长期以来依赖进口，该产 品的注册和上市将结束心外ePTFE心包膜依赖进口的历史。 基于庞大的治疗需求，国内心脏大血管外科手术量多年来保持持续增长，2024 年全国 ...

该产品为0.1mm的膨体聚四氟乙烯（ePTFE）膜，用于心脏外科手术中心包膜的修复或重建。人体的心 脏表面有一层薄膜包裹着整个心脏，这层薄膜被称为心包或心包膜，对心脏表面组织，特别是对冠状动 脉血管具有保护作用。每当需要进行心外手术时，都不可避免地要切开心包膜，由于心包的外科损伤所 致术后永久失去原有心包膜，以致导致心脏表面裸露与胸骨组织粘连，使得再行开胸手术时面临出血等 严重并发症的风险，致使手术难度增加，特别是小儿复杂先心病患者，很多都需要再次开胸。因此，开 心手术常规需要植用心包膜（ePTFE）修复或重建破损心包以保护心脏。目前国内市场所用的心包膜为 外企垄断，长期以来依赖进口，该产品的注册和上市将结束心外ePTFE心包膜依赖进口的历史。 格隆汇12月3日丨佰仁医疗(688198.SH)公布，近日，经国家药品监督管理局审查，公司研发的心包膜 （ePTFE）产品获批注册。 ...

Group 1 - The core point of the article is that Baijun Medical (688198.SH) has received approval from the National Medical Products Administration for its ePTFE product, which is used for the repair or reconstruction of the pericardium during cardiac surgeries [1] - The ePTFE membrane is 0.1mm thick and serves to protect the heart surface, particularly the coronary vessels, during surgical procedures [1] - The approval of this product will end the reliance on imported ePTFE pericardial membranes in the domestic market, which has been dominated by foreign companies for a long time [1] Group 2 - The pericardium is a thin membrane that envelops the heart, and surgical damage to it can lead to serious complications, especially in pediatric patients with complex congenital heart disease [1] - The need for ePTFE membranes in cardiac surgeries is critical, as they are routinely used to repair or reconstruct damaged pericardium to protect the heart [1] - The introduction of this product is expected to significantly impact the market by providing a domestic alternative to previously imported solutions [1]

Core Insights - The report highlights a positive growth trend in industrial enterprise profits for the first ten months of 2025, with a total profit of CNY 59,502.9 billion, reflecting a year-on-year increase of 1.9% [5][6] - The report emphasizes the impact of raw material prices on the profitability of industrial enterprises, indicating that these prices remain a significant drag on earnings [5][6] - A new consumption promotion plan issued by six ministries aims to optimize the supply structure of consumer goods by 2027, creating three trillion-level consumption sectors and ten hundred-billion-level consumption hotspots [8][9] Macroeconomic Overview - Industrial enterprises maintained a year-on-year profit growth, although the growth rate slowed by 1.3 percentage points compared to the previous three quarters [5] - In October, industrial profits saw a year-on-year decline of 5.5%, with a month-on-month drop of 27.1 percentage points [5] - The report notes that the mining sector's contribution to profits has been consistently low this year [5] Revenue and Cost Analysis - For the first ten months, industrial enterprises reported a revenue growth of 1.8%, with a slight decrease in revenue per hundred yuan of assets to CNY 74.5 [6] - Operating costs increased by 2.0%, with the profit margin remaining stable at 5.3% [6] - The report indicates that industrial production activities remain active, but pricing pressures persist, with PPI and production material PPI showing negative year-on-year growth [6][7] Consumption Promotion Plan - The plan aims for a significant optimization of the consumer goods supply structure by 2027, with a focus on new technologies and innovative business models [8][9] - It emphasizes the importance of matching supply with diverse consumer needs, including specific demographics such as children, students, and the elderly [10] - The report outlines the creation of new consumption scenarios and business formats, supported by a favorable development environment [11] Investment Recommendations - The report suggests focusing on companies related to employment, tourism, and cultural consumption, as well as those involved in sports events and creative industries [12]

Market Overview - The medical device sector experienced a decline of 1.21% on November 20, with Dongfang Ocean leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the medical device sector included: - Baijun Medical (688198) with a closing price of 131.90, up 4.02% [1] - Wandong Medical (600055) at 16.40, up 3.60% [1] - Yingke Medical (300677) at 38.90, up 3.43% [1] - Conversely, significant decliners included: - Dongfang Ocean (002086) at 2.85, down 4.36% [2] - Canar Co. (301122) at 26.52, down 3.70% [2] - Xiangyu Medical (688626) at 46.69, down 3.47% [2] Capital Flow - The medical device sector saw a net outflow of 1.303 billion yuan from institutional investors, while retail investors had a net inflow of 1.097 billion yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Individual Stock Capital Flow - Baijun Medical (688198) had a net inflow of 33.93 million yuan from institutional investors, while retail investors showed a net outflow of 16.04 million yuan [3] - Microelectrophysiology (688351) saw a net inflow of 17.57 million yuan from institutional investors, but a net outflow of 27.01 million yuan from retail investors [3] - Yingke Medical (300677) experienced a net inflow of 15.41 million yuan from institutional investors, with retail investors also showing a net outflow of 14.05 million yuan [3]

Core Insights - The report highlights that the fiscal data for October shows a slight narrowing in the year-on-year growth rate of tax revenue, with consumption-related tax categories maintaining a positive contribution [2][6][7] - It is anticipated that incremental policies will be expected towards the end of this year and the beginning of next year to support economic growth [6][9] Macroeconomic Overview - In October, total public fiscal revenue reached 22,614 billion yuan, representing a year-on-year increase of 3.2%, with tax revenue at 20,700 billion yuan, up 8.6% year-on-year [6][7] - Non-tax revenue fell to 1,914 billion yuan, down 33.0% year-on-year, indicating a significant decline [6][7] - The domestic value-added tax contributed positively to the tax revenue growth, increasing by 7.2% year-on-year, which boosted the overall tax revenue growth by 3.0 percentage points [7] - Public fiscal expenditure in October was 17,761 billion yuan, down 9.8% year-on-year, indicating a slowdown in spending [7][8] Government Fund Revenue and Expenditure - Central government fund revenue was 342 billion yuan, up 10.0% year-on-year, while local government fund revenue was 3,414 billion yuan, down 20.4% year-on-year [8] - The income from state-owned land use rights fell by 27.3% year-on-year, significantly impacting local government fund revenue [8] - Government fund expenditure totaled 5,968 billion yuan, down 38.2% year-on-year, with local government fund expenditure declining by 40.4% [8] Economic Growth Support - The report notes that the fiscal expenditure and financing pace have been front-loaded this year, supporting economic performance, with GDP growth of 5.2% year-on-year in the first three quarters of 2025 [9] - The upcoming central economic work conference and the "Two Sessions" in the new year are expected to provide important guidance on fiscal and policy financial tools [9]

Core Insights - The report highlights a potential rotation in consumer styles, driven by a recovery in CPI and favorable profit-valuation comparisons, suggesting that consumer sectors may experience a rebound [6][2][7] Company Summaries 1. China Eastern Airlines (600115.SH) - Notable inclusion in the November stock selection list, indicating positive sentiment towards the airline sector [1] 2. Baijiu Industry - The baijiu industry is experiencing a significant decline, with revenue and net profit growth rates of -5.8% and -6.9% respectively for the first three quarters of 2025. The third quarter saw a sharper decline with revenue and net profit growth rates of -18.5% and -22.1% respectively. The industry is transitioning from "over-competition" to "orderly competition" as companies reduce channel expenses to stabilize prices [8][7] 3. Baijun Medical (佰仁医疗) - The company reported a revenue of 382 million yuan for the first three quarters of 2025, a year-on-year increase of 30.58%. The net profit attributable to shareholders was 93 million yuan, up 57.93%. The third quarter alone saw a revenue of 134 million yuan, a 31.54% increase year-on-year, although net profit decreased by 9.39% [3][11][12] 4. Food and Beverage Sector - The food and beverage industry is expected to recover due to policies aimed at boosting consumer spending and improving macroeconomic data. The report notes that the core CPI has shown signs of recovery, with September and October figures at 1.0% and 1.2% respectively, indicating a positive trend in consumer prices [7][2][6] 5. Frozen Food and Beer Sectors - The frozen food sector is closely linked to the restaurant industry, with leading companies showing significant recovery as they adapt to market changes. The beer sector, while still facing challenges, is expected to benefit from the recovery in restaurant consumption in 2026 [9][8] 6. Consumer Spending - The report emphasizes that improving consumer spending is a key goal in the "14th Five-Year Plan," with a focus on enhancing domestic demand as a primary driver of economic growth. The contribution of final consumption expenditure to GDP growth has been higher than that of capital formation in recent years [7][6] 7. Research and Development in Baijun Medical - Baijun Medical has increased its R&D investment, with 118 million yuan spent in the first three quarters, accounting for 30.81% of its revenue. The company has several products in the approval process, which are expected to contribute to future growth [13][12][11]

Investment Rating - The investment rating for the company is "Buy" with a market price of RMB 108.83 and a sector rating of "Outperform" [1][5]. Core Insights - The company reported a revenue of RMB 382 million for the first three quarters of the year, representing a year-on-year growth of 30.58%. The net profit attributable to the parent company was RMB 93 million, up 57.93% year-on-year [5]. - The third quarter revenue was RMB 134 million, showing a year-on-year increase of 31.54%, while the net profit decreased by 9.39% year-on-year [5]. - The company is expected to continue launching new products, which will contribute to future growth, maintaining a positive outlook for the company's development [5][7]. Financial Performance Summary - For the years 2023 to 2027, the company is projected to achieve the following: - Revenue growth rates of 25.6% in 2023, 35.4% in 2024, and 37.5% in 2025 [9]. - Net profit growth rates of 21.1% in 2023, 27.0% in 2024, and 60.8% in 2025 [9]. - The estimated earnings per share (EPS) are expected to rise from RMB 0.84 in 2023 to RMB 3.27 in 2027 [9]. - The company maintains a high R&D expense ratio, with R&D expenses accounting for 30.81% of revenue in the first three quarters [10]. Product Development and Market Position - The company is in the process of launching multiple new products, with 8 products currently in the registration review phase [10]. - The collagen product line, particularly Collagen-I, is nearing approval and is expected to provide significant revenue growth [10].

Key Points - The report highlights a selection of stocks for November, including China Eastern Airlines, COSCO Shipping, and Ningde Times, indicating potential investment opportunities in these companies [1] - The report emphasizes the performance of China Petroleum, which reported a total revenue of 21,692.56 billion yuan for the first three quarters of 2025, a year-on-year decrease of 3.92%, while its net profit attributable to shareholders was 1,262.79 billion yuan, down 4.90% [8][9] - The report notes that the company has seen stable oil and gas production, accelerated development in renewable energy, and ongoing transformation in refining and chemical sectors, which enhances its competitive advantage across the entire industry chain [8][10] - For the food and beverage sector, Anjuke Food reported a revenue of 11.37 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 2.7%, while its net profit decreased by 9.3% [18][20] - The report indicates that Anjuke Food's third-quarter revenue reached 3.77 billion yuan, with a year-on-year growth of 6.6%, driven by strong performance in new channels [18][19] - In the electric equipment sector, JinkoSolar reported a significant year-on-year loss expansion, with total revenue of 36.809 billion yuan for the first three quarters of 2025, a decrease of 32.27% [14][15] - The report highlights that JinkoSolar's battery module shipment volume remained stable, with an increasing proportion of overseas shipments, indicating potential for recovery in profitability [14][15][16]

Core Insights - The stock price of Baijun Medical experienced a decline of 2.12% on November 4, reaching 110.60 CNY per share, with a total market capitalization of 15.235 billion CNY [1] - The company has seen a year-to-date stock price increase of 2.21%, with a 5-day increase of 0.55% and a 20-day increase of 5.35%, while experiencing a 60-day decline of 4.65% [1] Financial Performance - For the period from January to September 2025, Baijun Medical reported a revenue of 382 million CNY, reflecting a year-on-year growth of 30.58%, and a net profit attributable to shareholders of 92.697 million CNY, which is a 57.93% increase year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 374 million CNY, with 287 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 15.65% to 3,962, while the average circulating shares per person decreased by 13.31% to 34,767 shares [2] - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Times Pioneer Stock A and the entry of Yuanxin Yongfeng Ju You A as a new shareholder [3]